Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2023 | Final analysis of the DREAMM-2 trial: belantamab mafodotin for R/R multiple myeloma

Sagar Lonial • 7 Sep 2023
SOHO 2023
Multiple Myeloma Antibodies Belantamab mafodotin
DREAMM-2 DREAMM-5 DREAMM-6 DREAMM-8

Sagar Lonial, MD, Winship Cancer Institute of Emory University, Atlanta, GA, provides an update following the final analysis of the DREAMM-2 study (NCT03525678), and comments on other emerging trials evaluating belantamab mafodotin in patients with relapsed/refractory (R/R) multiple myeloma. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Sagar Lonial

1:05
Real-world comparison of RVD vs D-RVD in newly diagnosed transplant-eligible multiple myeloma
Sagar Lonial • 9 Dec 2023
0:45
The addition of daratumumab to RVD deepens treatment responses in t(11;14) multiple myeloma
Sagar Lonial • 9 Dec 2023
1:06
DeRIVE trial update: DId vs DVd in newly diagnosed MM
Sagar Lonial • 9 Dec 2023
Reaching a cure for multiple myeloma
Gareth Morgan et al. • 15 Apr 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals